3D ultrasound of removed cutaneous squamous cell carcinoma specimens

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults referred for surgical excision of primary cutaneous squamous cell carcinoma will have their routine excised specimen scanned ex vivo with a 3Sonic device connected to a high-frequency ultrasound to produce 3D tomographic images. One investigator, blinded to pathology, will interpret the ultrasound images and record the measured deep margin distance. A pathologist, blinded to the ultrasound results, will slice the entire specimen parallel to the ultrasound images and measure the histologic deep margin. A third investigator will match the ultrasound and histology images to compare the measured deep margins.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults with primary cutaneous squamous cell carcinoma.

Exclusion Criteria:

* Carcinomas located on the eyelids, vulva, penis, or perianal.
* Tumors with an anticipated excision larger than 60mm.

Where it's running

• Rigshospitalet
  Copenhagen, Denmark Recruiting

Study contacts

• Study coordinator: Linnea Langhans, MD, PhD
• Email: linnea.langhans@regionh.dk
• Phone: 35454755

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cemiplimab with Quad Shot Radiation for Head and Neck Cutaneous Squamous Cell Carcinoma

  This study tests whether giving cemiplimab together with a short course of Quad Shot radiation can be safely delivered in several rounds to elderly or frail patients with head and neck skin cancer.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · St Louis, Missouri · NCT07869823

• IDP-001 in advanced or metastatic solid tumors (including head and neck and skin cancers)

  A first- and second-phase study will test IDP-001 in people with advanced or metastatic solid tumors to see if it is safe and tolerable and to look for signs of activity.

  Recruiting at 6 sites Phase 1/2 InduPro, Inc. · Los Angeles, California and 5 other locations · NCT07602842

• Cosibelimab for tough CSCC in kidney transplant recipients or blood cancers

  This trial tests cosibelimab in people with advanced cutaneous squamous cell carcinoma who have a kidney transplant or certain blood cancers to see if it is safe and helpful for them.

  Recruiting at 2 sites Phase 4 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07426484

• Lifileucel (TIL) plus chemotherapy and IL-2 for advanced cutaneous squamous cell and Merkel cell carcinoma

  This trial will try lifileucel (tumor-infiltrating lymphocytes) combined with lymphodepleting chemotherapy and interleukin-2 in adults with unresectable or metastatic cutaneous squamous cell carcinoma or Merkel cell carcinoma who have previously received immunotherapy.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07288073

• Using blood tests to monitor skin cancer treatment

  This study is testing whether blood tests can help track how well treatment is working for people with skin cancer called cutaneous squamous cell carcinoma.

  Recruiting Massachusetts Eye and Ear Infirmary · Boston, Massachusetts · NCT06875609

• Using immunotherapy to treat cutaneous squamous cell carcinoma without surgery

  This study is testing if a combination of immunotherapy drugs can help patients with skin cancer avoid surgery.

  Recruiting Phase 2 The Netherlands Cancer Institute · Maastricht, Limburg and 4 other locations · NCT06823479

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.